

Cont
a¹
a²
8. (Amended) A host cell comprising a recombinant polynucleotide as defined in Claim 1 or a replicable vector comprising the polynucleotide [as defined in any one of Claims 1 to 7].

a²
a³
13. (Amended) A polypeptide according to Claim 10 [any one of Claims 10 to 12], which has migration stimulating factor activity.

24. (Amended) An antibody according to any one of Claims 14 to [24] 17 and 19 to 22 which is a monoclonal antibody.

a⁴
35. (Amended) A polynucleotide according to any one of Claims 31 to 33 [34], wherein the polynucleotide which encodes fibronectin or the polynucleotide which encodes the polypeptide as said or a natural variant thereof is a mRNA or a cDNA.

a⁵
39. (Amended) A method according to any one of Claims 36 to 38, wherein the reagent which can distinguish said polypeptide from fibronectin is an antibody according to any one of Claims 14 to 17 [18].

a⁶
44. (Amended) A method according to any one of Claims 36 to 38 and 40 to 42 [43], wherein the cancer is breast cancer.

a⁷
47. (Amended) A method of modulating cell migration the method comprising administering an effective amount of a polypeptide according to any one of Claims 10 and 12 [to 13] to the site where modulation of cell migration is required.

a⁸
49. (Amended) A method according to Claim 47 [or 48], wherein the site is in a mammalian body.

a⁹
51. (Amended) Use of a polypeptide according to any one of Claims 10 and 12 [to 13], in the manufacture of an agent for modulating cell migration.

52. (Amended) Use of a polypeptide according to any one of Claims 10 and 12 [to 13], for modulating cell migration.

53. (Amended) A method of healing a wound the method comprising administering to the locality of the wound an